natgillin/translations-raw huggingface dataset:
After reconstitution with 10 ml of water for injection, each ml contains 10 mg thiotepa. 
Nakon pripreme za primjenu s 10 ml vode za injekcije, svaki ml sadrži 10 mg tiotepe.
Cognitive disorder Cerebral haemorrhage 
Zatajenje bubrega Hemoragijski cistitis
20867 Caponago (MB) Italy Tel: +39 02 40700445 adienne@adienne.com 
Tel: +39 02 40700445 adienne@adienne.com
The recommended dose ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 2 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 185 mg/m2/dan (5 mg/kg/dan) do 481 mg/m2/dan (13 mg/kg/dan) podijeljena u jednu ili dvije dnevne infuzije, primijenjene tijekom 1 do 2 uzastopna dana prije alogene TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 555 mg/m
The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je 250 mg/m2/dan (10 mg/kg/dan) podijeljena u dvije dnevne infuzije primjenjene prije alogene TKMS, bez prekoračenja ukupne maksimalne kumulativne doze od 250 mg/m (10 mg/kg), tijekom cijelog pripremnog liječenja.
The recommended dose ranges from 200 mg/m2/day (8 mg/kg/day) to 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 200 mg/m2/dan (8 mg/kg/dan) do 250 mg/m2/dan (10 mg/kg/dan) podijeljena u dvije dnevne infuzije, primijenjene prije alogene TKMS, bez prekoračenja ukupne maksimalne kumulativne doze od 250 mg/m
What you need to know before you use TEPADINA Do not use TEPADINA 
Što je TEPADINA i za što se koristi Što morate znati prije nego počnete primjenjivati lijek TEPADINA
Investigation 
Pretrage
TEPADINA must be reconstituted with 10 ml of sterile water for injection. 
TEPADINA se mora rekonstituirati s 10 ml sterilne vode za injekcije.
TRM values ranged from 0% to 30% confirming the safety of the conditioning treatment including thiotepa for allogeneic HPCT in paediatric patients with haematological diseases. 
TRM vrijednosti su bile u rasponu od 0% do 30% potvrđujući sigurnost pripremnih terapija s tiotepom za alogene TKMS u pedijatrijskih bolesnika s hematološkim bolestima.
Dysuria Oliguria Renal failure Cystitis Haematuria 
Oligurija Zatajenje bubrega Cistitis
TEPADINA is supplied as 15 mg powder for concentrate for solution for infusion. 
TEPADINA dolazi u obliku 15 mg praška za koncentrat za otopinu za infuziju.
TEPADINA 100 mg powder for concentrate for solution for infusion Thiotepa 
TEPADINA 100 mg prašak za koncentrat za otopinu za infuziju tiotepa
Rash Pruritus Alopecia 
Svrbež Alopecija
Engraftment: It has been achieved with all reported conditioning regimens including thiotepa. 
Prihvat transplantata: Prihvat je postignut kod svih pripremnih terapija sa tiotepom.
TEPADINA is supplied as 100 mg powder for concentrate for solution for infusion. 
TEPADINA dolazi u obliku 100 mg praška za koncentrat za otopinu za infuziju.
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 2.5% to 29% have been reported. 
Mortalitet vezan za terapiju (RRM - Regimen Related Mortality ) i mortalitet vezan za transplantaciju (TRM - Transplant Related Mortality): prijavljene su RRM vrijednosti u rasponu od 2,5% do 29%.
Hearing impaired 
Oštećenje sluha
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 2% have been reported. 
Mortalitet vezan za terapiju (RRM - Regimen Related Mortality ) i mortalitet vezan za transplantaciju (TRM - Transplant Related Mortality): prijavljene su RRM vrijednosti u rasponu od 0% do 2%.
Injection site inflammation Injection site pain Mucosal inflammation 
Upala na mjestu injiciranja Bol na mjestu injiciranja
PRESENTATION 
Primjena
Haemorrhage 
TALASEMIJA
TEPADINA 15 mg powder for concentrate for solution for infusion Thiotepa 
TEPADINA 15 mg prašak za koncentrat za otopinu za infuziju tiotepa
TEPADINA is used to prepare patients for bone marrow transplantation. 
TEPADINA se koristi za pripremu bolesnika za transplantaciju koštane srži; djeluje uništavajući stanice koštane srži.
Disposal 
Deskvamacija
ALLOGENEIC HPCT 
ALOGENA TKMS
Allogeneic HPCT 
Alogena TKMS
Preparation of TEPADINA 
Priprema lijeka TEPADINA
Tachycardia Cardiac failure 
Tahikardija Zatajivanje srca
SICKLE CELL ANAEMIA 
Pireksija Astenija Zimica
How to store TEPADINA 
Kako čuvati lijek TEPADINA
Intracranial aneurysm Extrapyramidal disorder 
Intrakranijska aneurizma Ekstrapiramidni poremećaji Kognitivni poremećaji Cerebralno krvarenje
The recommended dose in haematological diseases ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. 
LIMFOM Preporučena doza je u rasponu od 125 mg/m2/dan (3,38 mg/kg/dan) do 300 mg/m2/dan (8,10 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 2 do 4 uzastopna dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 900 mg/m
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 2.5% have been reported. 
Mortalitet vezan za terapiju (RRM - Regimen Related Mortality ) i mortalitet vezan za transplantaciju (TRM - Transplant Related Mortality): prijavljene su RRM vrijednosti u rasponu od 0% do 2,5%.
The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 3 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2 (20.27 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 125 mg/m2/dan (3,38 mg/kg/dan) do 250 mg/m2/dan (6,76 mg/kg/dan) podijeljena u jednu ili dvije dnevne infuzije, primijenjene tijekom 3 do 4 uzastopnih dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 750 mg/m
Cataract 
Katarakta
The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. 
REFRAKTORNA CITOPENIJA Preporučena doza je 125 mg/m2/dan (5 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 3 uzastopna dana prije alogene TKMS, bez prekoračenja ukupne maksimalne kumulativne doze 375 mg/m
The recommended dose in solid tumours ranges from 150 mg/m2/day (6 mg/kg/day) to 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered from 2 up to 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2 (42 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 150 mg/m2/dan (6 mg/kg/dan) do 350 mg/m2/dan (14 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 2 do 3 uzastopna dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 1050 mg/m
The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je 125 mg/m2/dan (5 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 2 uzastopna dana prije alogene TKMS, bez prekoračenja ukupne maksimalne kumulativne doze 250 mg/m
Each TEPADINA vial must be reconstituted with 10 ml of sterile water for injection. 
Rekonstitucija TEPADINA se mora rekonstituirati s 10 ml sterilne vode za injekcije.
The recommended dose ranges from 150 mg/m2/day (4.05 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2 (20.27 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 150 mg/m2/dan (4,05 mg/kg/dan) do 250 mg/m2/dan (6,76 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 3 uzastopna dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 750 mg/m
(8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. 
300 mg/m2/dan (8,10 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 2 do 4 uzastopna dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 900 mg/m
Enteritis Intestinal obstruction 
Oštećenje bubrega
The recommended dose in solid tumours ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2 (21.62 mg/kg), during the time of the entire conditioning treatment. 
Preporučena doza je u rasponu od 120 mg/m2/dan (3,24 mg/kg/dan) do 250 mg/m2/dan (6,76 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 3 do 5 uzastopnih dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 800 mg/m
The recommended dose ranges from 250 mg/m2/day (10 mg/kg/day) to 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2 (42 mg/kg), during the time of the entire conditioning treatment. 
TUMORI CNS-a Preporučena doza je u rasponu od 250 mg/m2/dan (10 mg/kg/dan) do 350 mg/m2/dan (14 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 3 uzastopna dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 1050 mg/m
The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m2 (5 mg/kg), during the time of the entire conditioning treatment. 
MULTIPLI MIJELOM Preporučena doza je 185 mg/m2/dan (5 mg/kg/dan) u jednoj dnevnoj infuziji prije alogene TKMS, bez prekoračenja ukupne maksimalne kumulativne doze od 185 mg/m
Tel.: +48 22 577 28 00 
Accord Healthcare Polska Sp. z o.o. Tel.: +48 22 577 28 00
Pulmonary oedema Cough 
Plućni edem Epistaksa
Tel: +48 22 577 28 00 
Accord Healthcare Polska Sp. z o.o. Tel: +48 22 577 28 00
Arrhythmia 
Dojenje
The recommended dose is 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m2 (13.51 mg/kg), during the time of the entire conditioning treatment. 
RAK JAJNIKA Preporučena doza je 250 mg/m2/dan (6,76 mg/kg/dan) u jednoj dnevnoj infuziji, primjenjenoj tijekom 2 uzastopna dana prije autologne TKMS, bez prekoračenja ukupne maksimalne kumulativne doze od 500 mg/m
Cardiac disorders 
Srčani poremećaji Aritmija
Hypopituitarism 
Hipopituitarizam
The European Commission issued a decision on this opinion on 11/11/2016. 
Europska komisija objavila je odluku o tom mišljenju 11. 11. 2016.
Clenil is marketed in the following EU Member States: France, Germany, Greece, Ireland and Italy. 
Clenil je stavljen u promet u sljedećim državama članicama EU-a: Francuskoj, Njemačkoj, Grčkoj, Irskoj i Italiji.
The areas harmonised include: 
Područja koja se trebaju uskladiti obuhvaćaju:
EMA/612121/2016 Rev.1 EMEA/H/A-30/1418 
EMA/612121/2016 Rev.1 EMEA/H/C/-30/1418
It is also available under the trade names of Becloneb, Beclospin and Sanasthmax. 
Također je dostupan pod trgovačkim nazivima Becloneb, Beclospin i Sanasthmax.
The lowest dose needed to control symptoms should be used. 
Potrebno je primjenjivati najnižu dozu potrebnu za kontroliranje simptoma.
Why was Clenil reviewed? 
Zašto je Clenil ponovno ocjenjivan?
Regular follow-up is recommended to review the treatment response. 
Preporučuje se redovno praćenje radi ocjene odgovora na liječenje.
The maximum daily dose is 3,200 micrograms in adults and adolescents (up to 1,600 micrograms taken twice a day) and 1,600 micrograms in children below 12 years (up to 800 micrograms taken twice a day). 
Maksimalna dnevna doza jest 3 200 mikrograma u odraslih osoba i adolescenata (do 1 600 mikrograma koji se uzimaju dvaput na dan) te 1 600 mikrograma u djece mlađe od 12 godina (do 800 mikrograma koji se uzimaju dvaput na dan).
The duration of treatment should not exceed 3 months, unless a diagnosis of asthma is likely. 
Trajanje liječenja ne smije biti dulje od tri mjeseca, osim ako postoji vjerojatnost za dijagnozu astme.
What is Clenil? 
Što je Clenil?
Clenil has been authorised in the EU via national procedures. 
Lijek Clenil odobren je u EU-u u okviru nacionalnih postupaka.
It is also used to treat recurrent wheezing (whistling sound made while breathing, caused by narrowed airways or inflammation) in children up to 5 years of age. 
Također se primjenjuje za liječenje ponavljajućeg piskanja (zvuk zviždanja prilikom disanja prouzročen suženim dišnim putovima ili upalom) u djece u dobi do pet godina.
The Committee also harmonised other sections of the SmPC including sections 4.6 (fertility, pregnancy and lactation), 4.8 (side effects), and 5.1 (pharmacodynamics). 
Odbor je također uskladio druge dijelove Sažetka opisa svojstava lijeka, uključujući dijelove 4.6. (plodnost, trudnoća i dojenje), 4.8. (nuspojave) i 5.1. (farmakodinamika).
The starting dose of Clenil depends on the frequency and severity of symptoms and it can be adjusted until symptoms are under control. 
Početna doza lijeka Clenil ovisi o učestalosti i ozbiljnosti simptoma te se može prilagođavati dok su simptomi pod kontrolom.
Clenil is a medicine used for the maintenance treatment of asthma in adults and children. 
Clenil je lijek koji se primjenjuje u terapiji održavanja za liječenje astme u odraslih osoba i djece.
The company that markets these medicines is Chiesi and associated companies. 
Te lijekove stavlja u promet tvrtka Chiesi i povezane tvrtke.
This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed. 
To je dovelo do odstupanja među državama članicama u pogledu načina primjene lijeka, što je vidljivo u razlikama među sažecima opisa svojstava lijeka, označivanju i uputama o lijeku u državama u kojima se lijek stavlja u promet.
Having harmonised the indication, the CHMP also harmonised recommendations on the doses. 
Nakon usklađivanja indikacija CHMP je također uskladio preporuke o načinu doziranja.
However, the Committee considered that Clenil can be used to treat recurrent wheezing in children up to 5 years of age because this use is supported by adequate data. 
Međutim, Odbor je smatrao da se lijek Clenil može primjenjivati za liječenje ponavljajućeg piskanja u djece u dobi do pet godina jer je ova primjena poduprta odgovarajućim podacima.
On 19 June 2015, the Italian medicines regulatory agency referred the matter to the CHMP in order to harmonise the marketing authorisations for Clenil and associated names in the EU. 
Talijanska regulatorna agencija za lijekove uputila je 19. lipnja 2015. predmet CHMP-u radi usklađivanja odobrenja za stavljanje u promet lijeka Clenil i povezanih naziva u EU-u.
If no treatment benefit is observed within 2-3 months or if a diagnosis of asthma is not likely, Clenil should be discontinued to avoid unnecessary long-term exposure to inhaled corticosteroids and associated risks in children. 
Ako unutar 2 - 3 mjeseca nisu zabilježene koristi liječenja ili dijagnoza astme nije vjerojatna, potrebno je obustaviti liječenje lijekom Clenil radi sprečavanja nepotrebnog dugotrajnog izlaganja djece inhalacijskim kortikosteroidima i povezanim rizicima.
It is available as a suspension given by inhalation though a nebuliser device, and in asthma it should only be used when the use of other hand-held inhalers is not appropriate. 
Dostupan je u obliku suspenzije koja se daje udisanjem s pomoću nebulizatora, a u slučaju astme treba se primjenjivati samo ako primjena drugih ručnih inhalatora nije odgovarajuća.
Clenil contains the active substance beclometasone dipropionate (which belongs to a group of antiinflammatory medicines commonly known as ‘corticosteroids'). 
Clenil sadržava djelatnu tvar beklometazon dipropionat (koji pripada skupini protuupalnih lijekova pod zajedničkim nazivom „kortikosteroidi”).
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Clenil in the European Union (EU). 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je da postoji potreba za usklađivanjem informacija o propisivanju lijeka Clenil u Europskoj uniji (EU).
Questions and answers on Clenil and associated names (beclometasone dipropionate, 400 and 800 microgram nebuliser suspension) EMA/612121/2016 Rev.1 
Pitanja i odgovori o lijeku Clenil i povezanim nazivima (beklometazon dipropionat, suspenzija za atomizator od 400 i 800 mikrograma) EMA/612121/2016 Rev.1
In children with recurrent wheezing the response to treatment should be carefully monitored; if no benefit is observed within 2-3 months, Clenil should be discontinued. 
U djece s ponavljajućim piskanjem potrebno je pozorno pratiti odgovor na liječenje; ako se unutar 23 mjeseca ne uoče koristi, potrebno je obustaviti liječenje lijekom Clenil.
In children up to 5 years of age, the decision to start Clenil for the treatment of recurrent wheezing should be determined by the severity and frequency of the wheezing episodes. 
U djece u dobi do pet godina odluku za početak primjene lijeka Clenil za liječenje ponavljajućeg piskanja treba donijeti na temelju ozbiljnosti i učestalosti epizoda piskanja.
Questions and answers on Clenil and associated names (beclometasone dipropionate, 400 and 800 microgram nebuliser suspension) 
Pitanja i odgovori o lijeku Clenil i povezanim nazivima (beklometazon dipropionat, suspenzija za atomizator od 400 i 800 mikrograma)
The Committee agreed that Clenil should no longer be used to treat common bronchostenotic conditions (narrowing of the airways in the lungs) because of the lack of rigorous evidence from adequately designed clinical studies. 
Odbor se složio da se lijek Clenil više ne bi smio primjenjivati za liječenje uobičajenih bronhostenotičkih stanja (sužavanja dišnih putova u plućima) zbog nedostatka čvrstih dokaza iz odgovarajuće izrađenih kliničkih ispitivanja.
The CHMP agreed that Clenil can be used for the maintenance treatment of asthma in adults and children when the use of pressurised or dry powder inhalers is unsatisfactory or inappropriate. 
CHMP se složio da se lijek Clenil može primjenjivati u odraslih osoba i djece u terapiji održavanja za liječenje astme ako je primjena inhalatora s tlačenim inhalatom ili suhim praškom nezadovoljavajuća ili neodgovarajuća.
The CHMP also agreed that Clenil should no longer be used to treat allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example hay fever or allergy to dust mites) because the available data do not support this use and other medicines available as nasal sprays may be better tolerated. 
CHMP se također složio da se lijek Clenil više ne bi smio primjenjivati za liječenje alergijskog rinitisa (upale nosne šupljine prouzročene alergijom, primjerice peludnom groznicom ili alergijom na grinje) jer ta primjena nije poduprta dostupnim podacima te bi se bolje mogli podnositi drugi dostupni lijekovi u obliku sprejeva za nos.
The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU. 
U svjetlu dostavljenih podataka i znanstvene rasprave u okviru Odbora, mišljenje je CHMP-a da se sažeci opisa svojstava lijeka, označivanje i upute o lijeku moraju uskladiti na razini EU-a.
On 15 September 2016, the European Medicines Agency completed a review of Clenil. 
Europska agencija za lijekove dovršila je ocjenjivanje lijeka Clenil 15. rujna 2016.
Clenil was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh). 
Koordinacijska skupina za postupak međusobnog priznavanja i decentralizirani postupak za humane lijekove (CMDh) utvrdila je da je u pogledu lijeka Clenil potrebno provesti usklađivanje.
Tmax is between 3 and 8 hours. 
Vrijednost Tmax je između 3 i 8 sati.
8501 Novo mesto SLOVENIA 
8501 Novo mesto SLOVENIJA
BLISTER (PVC/PVDC-Alu FOIL) 
BLISTER (PVC/PVDC-Alu FOLIJA)
- Do not take a double dose to make up for a forgotten dose. 
- Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu tabletu.
- The other ingredients (excipients) are: 
- Ostali sastojci (pomoćne tvari) su:
Continue to take Marixino as long as it is of benefit to you. 
Nastavite uzimati Marixino onoliko dugo koliko od nje imate koristi.
Marixino with food and drink 
Marixino s hranom i pićem
Memantine should not be used during pregnancy unless clearly necessary. 
Memantin se ne smije upotrebljavati tijekom trudnoće, osim ako to nije izričito potrebno.
Paediatric population No data available. 
Pedijatrijska populacija Nema dostupnih podataka.
Other medicines and Marixino 
Drugi lijekovi i Marixino
Children and adolescents Marixino is not recommended for children and adolescents under the age of 18 years. 
Djeca i adolescenti Marixino se ne preporučuje za djecu i adolescente mlađe od 18 godina.
Some factors that may raise urine pH (see section 5.2 'Elimination') may necessitate careful monitoring of the patient. 
Neki čimbenici koji mogu povisiti pH mokraće (vidjeti dio 5.2 “Eliminacija”) mogu zahtijevati pažljivo nadziranje bolesnika.
It belongs to a group of medicines known as anti-dementia medicines. 
On pripada skupini lijekova poznatih kao lijekovi protiv demencije.
Your doctor should assess your treatment on a regular basis. 
Liječnik treba redovito procjenjivati Vaše liječenje.
If you forget to take Marixino - If you find you have forgotten to take your dose of Marixino, wait and take your next dose at the usual time. 
Ako ste zaboravili uzeti Marixino - Ako ustanovite da ste zaboravili uzeti dozu lijeka Marixino, pričekajte i uzmite sljedeću dozu u uobičajeno vrijeme.
The volume of distribution is around 10 l/kg. 
Volumen raspodjele je oko 10 l/kg.